Eric Dobmeier resigned as COO of Seattle Genetics Inc., effective Jan. 1, 2018.
Dobmeier resigned to assume the CEO position with a private biotech company.
Seattle Genetics COO resigns
A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research
2021 Year in Review: Highlighting Key Investment Banking Trends
Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings
Global M&A By the Numbers: Q3 2021
Eric Dobmeier resigned as COO of Seattle Genetics Inc., effective Jan. 1, 2018.
Dobmeier resigned to assume the CEO position with a private biotech company.